KRAS Knockout cell line (HEK293)

location： Home > Products > KO Cell Lines > KRAS Knockout cell line (HEK293)

Ocular, Otolaryngologic and Oral System

Skeleton, Articulus, Soft Tissue, Derma System

Ocular, Otolaryngologic and Oral System

Skeleton, Articulus, Soft Tissue, Derma System

Ocular, Otolaryngologic and Oral System

Skeleton, Articulus, Soft Tissue, Derma System

Ocular, Otolaryngologic and Oral System

Skeleton, Articulus, Soft Tissue, Derma System

Cell Monoclonal Culture Medium

Monoclone Genotype Validation Kit

KRAS Knockout cell line (HEK293) Order

Catalog#：YKO-H710

Price (USD)：-

Size： 1*10^6

Instruction：

Exclusive Red Cotton system（en.rc-crispr.com）was used to design the sgRNA fragment knockout strategy. Two sgRNAs were constructed into CRISPR-U™ plasmid which will be subsequentially transfected into cells by electroporation/virus method. And the single-cell clones were isolated by the limited dilution method and the Monoclone Genotype Validation Kit (Cat: YK-MV-1000) was used for cell lysis and PCR amplification on the single-cell clones, and then the genotype was verified by Sanger sequencing. Upon passing the final validation, the positive clones were expanded and cryopreserved.

Detailed Product Information Recommended Companion Products

Cell Info

Catalog	YKO-H710
Cell line	KRAS Knockout cell line(HEK293)	Cell Type	Human Embryonic Kidney Cell Line
Morphology	Epithelial-like, adherent	Passage ratio	1:4~1:6
Culture method	90%DMEM+10% FBS
Cryopreservation solution	50%DMEM+40% FBS+10%DMSO
Special Note

STR Validation

Gene Information

Official symbol

KRAS

Gene id

3845

Official full symbol

KRAS proto-oncogene, GTPase

Also known as

'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras, K-Ras 2, KI-RAS, KRAS1, KRAS2, NS, NS3, OES, RALD, RASK2, c-Ki-ras, c-Ki-ras2

This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region.